Background. Hemophagocytic lymphohistiocytosis (HLH) is a catastrophic syndrome of unrestrained immune activation. Evaluation and management of HLH in the tropics is challenging. Objectives. To examine the reported etiologies and management of HLH reported from the sub-continent. Methods. Systematic review of all published cases from the Indian sub-continent. Results. We found only 156 published cases of HLH from the sub-continent. HLH was reported from the immediate perinatal period to 46 years of age. Infection-associated HLH (IAHS) constituted 46.8% of all cases of HLH (44% and 51% in children and adults respectively). In adults, tropical infections triggered 51% of these cases of IAHS. Steroids were used in 47% of children and 10% of adults. Etoposide and/or cyclosporine were used in 8% children and 8% of adults only. Intravenous immunoglobulin was used in another 30% of children and 4% of the adults. HLH-related mortality occurred in 31.8% and 28% of children and adults respectively. Conclusions. HLH is under-reported in the sub-continent and has high mortality. Cyclosporine and etoposide are seldom administered early despite diagnosis of HLH. Larger cohorts with IAHS triggered by tropical infections are urgently needed to understand its natural history and implications of this differing prescription pattern on mortality.
Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal syndrome secondary to immune hyperactivation (1) . HLH may be genetic in origin or arise secondary to infectious, rheumatologic, malignant or metabolic disorders (Table 1) .
Irrespective of cause, the unrestrained immune hyperactivation characteristic of this syndrome leads to host tissue damage (2) . The diagnosis of this syndrome is cur- rently based on meeting the HLH-2004 criteria (Table 2) . In the tropics, especially in adults, infections are common triggers of HLH (3) and the prevalence of perforin mutations is unknown. The clinical features of tropical infectious triggers can overlap with that of HLH and the diagnosis of the inciting etiology can be challenging (Table 3 ) (4). 6 . Low or absent NK-cell activity (according to local laboratory) 2 7. Ferritin ≥500/ µg/dl 8. Soluble CD25 (Soluble Interleukin-2 receptor) ≥2400 U/ml 3 1 Hemophaogcytosis may be absent at initial evaluation; repeated marrow and/or tissue aspirates and biopsies may be needed; 2 Sustained low NK cell activity suggests perforin and/or granzyme pathyway abnormality and screening for CD107a (LAMP-1 cell surface expression by cytometry) expression is recommended; NK-cell activity may be transiently depressed in IAHS. Persistent NK-cell activity depression even in the face of clinical resolution and absent known mutations should trigger referral for bone marrow transplantation. 3 This is the most sensitive biochemical test and levels co-relate with response and prognosis; levels are age-dependent and local data needs to be ascertained. (5). We performed a systematic review to identify the common etiologic triggers of HLH and suggest an appropriate initial etiologic evaluation and management strategy for HLH in the sub-continent.
Methods

Literature search
Two of the authors (Dr. R.S and Dr. N.S) conducted a systematic search of English literature independently using the terms "hemophagocytosis", "hemophagocytic lymphohistiocytosis" "Macrophage activation" and "Asia" or "India" in the MEDLINE, OVID and CINAHL databases. This was further supplemented by search of IndMED, the internet search engine GOOGLE and a hand search of the references and our personal databases for published cases of hemophagocytic lymphohistiocytosis from the Indian sub-continent including India, Pakistan, Sri Lanka, Bangladesh, Nepal and Bhutan.
Only those articles were included for analysis which were reported in English literature and included patients with diagnosed HLH fulfilling the 2004 criteria of the Histiocyte society as evidenced by 1) genetic diagnosis of HLH or 2) At least 5 out of the 8 criteria for clinical diagnosis of HLH (Table 1) .
Data extraction
Both the abstracts and full text articles, where available, were reviewed. Where neither was available, the authors were mailed for data on their published cases. Data was extracted in a pre-designed data extraction form regarding the age, sex, etiology of HLH, treatment of HLH administered and outcomes. Data was extracted and expressed in a descriptive fashion (Mean, SD; Table 4 )
Results
Our search yielded 682 references. This included 156 cases of HLH (Table 4 A&B) in 56 published reports, including 63 adults (≥8 years of age) and 93 children.
Full text or abstracts were available for all 156 cases in the articles reviewed . An additional 24 reports were excluded because they reported cases from outside the subcontinent, they did not meet current criteria for HLH (60) (61) (62) (63) (64) or did not report any new case of HLH (65) . Cases reported in duplicate were not included for the analysis (26) .
HLH was reported from the immediate perinatal period (55) Continuation of Table 4B Systematic search of all published reports of HLH in pediatric patients published from South Asian subcontinent
In adults, no confirmed or probable case of FLH has been reported from the sub-continent. Infections were reported as the most common triggers for HLH. In adults, tropical infectious diseases were reported to have triggered 51% (32/63) of the cases of HLH [Visceral leishmaniasis (VL) 40.6% (13/32), Rickettsia 18.8% (6/32), Malaria 15.6% (5/32), Histoplasmosis 12.5% (4/32), Enteric fever 9.4% (3/32), Tuberculosis 1/32]. Viral agents were reported as possible triggers in another 30% (19/63) cases of HLH, but the etiologic agent was unrecognized in 68.5% of cases (13/18) . Where an etiologic agent was reported, EBV 16.7% (3/18) and Parvovirus B19 (11.1%) were the triggers most often. Connective-tissue disease and malignancy were other important recognized triggers in adults (9.5%, 6/63 and 4.8%, 3/63 respectively).
Data on the use of immunomodulatory treatments for HLH were available in 93.5% (87/93) and 79.4% (50/63) of adults. Steroids were the most common immunomodulatory agents used in 47% (41/87) of children and 10% (5/50) of adults. Etoposide and/or cyclosporine were used in 8% (7/87) children and 4/50 (8%) of adults only. Intravenous immunoglobulin (IVIG) was used in another 30% of children (26/87) and 2/63 (4%) of the adult cases reviewed. HLH-related mortality occurred in 31.8% (29/91) and 28% (17/61) of children and adults respectively.
Discussion
Hemophagocytic lymphohistiocytosis (HLH) is an entity which presents major diagnostic and therapeutic challenges (1) . HLH is a clinical syndrome secondary to hyper-cytokinemia and organ infiltration by phagocytizing histiocytes (Figure 1 ) resulting from defects in critical regulatory pathways responsible for the termination of inflammatory responses (1, 2) .
This entity is often under-recognized, especially in adults, and specific therapy is not considered early in the disease course. Our systematic review found less than 160 cases in a population of 1.2 billion, indicating under-recognition of this entity. Most cases were single reports and most of these reports clustered around the same centers across the sub-continent (Table 4 A&B) . Given the prevalence of the tropical triggers of HLH in the sub-continent, the possibility of under-diagnosis remains highly likely, especially in adults. One of the largest series and a seminal report of HLH from India was not included as it did not fulfill the current requirements for diagnosis of HLH (60) . Genetic HLH may be: familial (FHL), autosomal recessive], sporadic (sHLH) or complicate certain well characterized syndromes involving defects in the cytolytic Tcell pathway (Table 1 ). FHL has an estimated incidence of around 1:50,000 and is invariably fatal if untreated, with a median survival of two months. The presentation is often in infancy, though onset in adolescence and adults is well known. The family history may be non-contributory, given the recessive nature of inheritance and the absence of large families (66) ; furthermore, FHL may often be triggered by infections. Infections, notably Epstein-Barr virus, are another leading cause of HLH (67) . Salmonella, tuberculosis, malaria and leishmaniasis are tropical infections that are well-recognized triggers of infection-associated hemophagocytosis (IAHS) ( Table 1 ). In the tropics, infections are overwhelmingly the most common triggers of HLH. In our systematic review, age was not a predictor of etiology of HLH. Tuberculosis has been reported in the neonatal period (55) when FLH is usually prevalent in the Western world. Caution is however required in interpreting our results. The authors did not use a common etiologic evaluation panel, evaluation was often limited, unknown triggers constitute a large sub-group and genetic tests for FLH were seldom done, even in children.
The clinical features of HLH, secondary to such unrestrained immune activation, are not specific and mimic tropical infections (VL, disseminated tuberculosis, and severe malaria), hematological malignancy and auto-immune disease in adults. The diagnosis of HLH is made by fulfilling the revised HLH criteria (1) ( Table 2 ) which were primarily designed to select enrollment into clinical trials. The sensitivity of these criteria for early HLH is unknown given the lack of a gold standard test. Importantly, the clinical picture might be aggressive and the diagnostic criteria might not be fulfilled at onset, making management extremely challenging. In particular, the finding of bone marrow hemophagocytosis is not sensitive for the diagnosis of HLH or the underlying trigger (4, 43) . Also, the finding of isolated marrow hemophagocytosis in the absence of the clinical syndrome does not qualify for the diagnosis of HLH (Table 2 ). In the West and South-East Asia, IAHS is usually viral (EBV)-triggered and a distinction between FHL and IAHS at onset is not made; indeed, delay in administration of etoposide to cases of EBV-related HLH is associated with increased mortality. In contrast, tropical HLH may be triggered by tuberculosis, VL, Salmonella, Plasmodium, dengue or Parvovirus B19. Several case reports and small series suggest that the natural history of IAHS may be different from EBV-triggered HLH (3, 5, 18) .
The HLH-2004 protocol uses upfront cyclosporine [with etoposide, dexamethasone] and intrathecal methotrexate for patients with neurological signs, persistent active CNS disease and CNS reactivation of HLH. All children with familial disease, known mutations, severe and persistent non-familial disease and relapsed HLH are treated with continuation phase etoposide, dexamethasone, and CSA. Stem-cell transplantation is performed as early as possible, when an acceptable donor is available. Therapy is discontinued otherwise at remission (8 weeks) as the completed regimen for patients with possible sHLH and viral-triggered HLH. Patients with refractory disease are treated with ATG, rituximab or alemtuzumab for remission induction. Our systematic review shows that steroids and IVIG (in children) are the common regimens reported; the use of CSA and/or etoposide was very low. The reasons for this may include fulminant presentation, late recognition, the inability to rule out tropical-triggers of HLH, physician perception on the differing profiles of nonviral infection-triggered HLH and severe cytopenia (4) . Data from systematic reviews suggest that HLH secondary to VL, tuberculosis, malaria and dengue may recover with early anti-microbial therapy and steroids alone. Indeed, the major correlate with mortality is the time to diagnosis (and treatment) of the offending pathogen. Further, the coexisting organ dysfunction due to HLH may also complicate drug administration [e.g. anti-tubercular drugs and HLH-related liver dysfunction, cytopenia and etoposide dose]. Our adult series also highlights these difficulties; infections were the most common triggers (80%; 10% unknown), short presentation was (median 11 days, IQR 9.25-30) and HLH criteria not being fulfilled at ICU admission median of 4 (IQR 2-4.25) (3).
A uniform protocol for rapid early evaluation of suspected HLH and initiation of therapy (Table 5 , Figure 2 ) is important.
Such a protocol, especially in adults, should balance the exhaustive search for tropical triggers and early initiation of HLH-2004 (including etoposide) in patients with viral-triggered HLH and patients with tropical infection-triggered HLH not responding to steroids alone (Figure 2 ). Table 5 Summary of suggested evaluation of a suspected patient with hemophagocytic lymphohistiocytosis in the Indian sub-continent Lastly, multi-centric prospective data from the sub-continent with such a common evaluation protocol and longitudinal outcomes in cohorts of patients with IAHS will clarify the etiology, management and outcomes of HLH in the sub-continent and whether the prescription patterns in the sub-continent merit reconsideration.
Conclusions
In conclusion, HLH is a catastrophic and fulminant clinical syndrome of immune activation. Heightened clinical recognition of this entity and early evaluation with rapid initiation of treatment may help in better outcomes. More data and multi-centric prospective studies from the tropics are urgently required.
